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strong trend toward better BPFS (p=0.079). In multivariate analysis only EBRT dose was signiﬁcant for BPFS (p=0.035; Exp(B):15.24;
95%CI:1.21–191).
Conclusions. Dose escalation ≥72Gy was associated with increased BPFS rates. Higher EBRT doses mainly beneﬁt patients referred
to salvage-EBRT but who previously met adjuvant-EBRT criteria.
http://dx.doi.org/10.1016/j.rpor.2013.03.481
Evaluating the effectiveness of MRI in the initial therapeutic strategy in prostate cancer. Our experience
M. Pérez Martín, R. del Castillo Acun˜a, F. Peracaula Espino
Hospital Punta de europa, Servicio de Oncología Radioterápica, Spain
Evaluation of local disease extend is typically accomplished with the combination of digital rectal examination (DRE) and tran-
srectal ultrasound at the time of biopsy. Magnetic resonance imaging (MRI) is widely available in our department, and therefore
we usually apply it in the initial evaluation of men with newly diagnosed prostate cancer. The aim of this descriptive study is to
evaluate all prostate cancer patients who were undergone external radical external beam radiotherapy (EBRT) in our department
and to know how many of them have a MRI. Likewise, to determine if there is a therapeutic change in the initial strategy. Between
January 2009 and November 2012 were included 198 patients with newly diagnosed prostate who received EBRT. Patients with
a previous prostatectomy and palliative patients were excluded. Age average 69 years old (50–83), originally we arrange by risk
of recurrence according DRE, PSA and Gleason, we obtained 27.8% Low Risk, 41.4% Intermediate Risk and 30.8% High Risk. 80%
of whole of them received androgen deprivation therapy (ADT), so 10% received ADT without selection criteria by urologist. 114
patients (57%) had a MRI, 31 of them there was a therapeutic change, almost in 30% of the patients with MRI. Of them, 10 patients
could be changed at total length of ADT or planning tumor volumes (PTV) and 21 patients this therapeutic change consisted
of both, planning tumor volumes (PTV) and total length of ADT. 57 patients were found with a different clinical stage. In our
experience MRI is additional tool to staging prostate cancer, overall we think is useful to determine extracapsular invasion, when
Gleason ≥8 or Gleason 7 (4 + 3), besides of that cases which DRE do not provide a clear information.
http://dx.doi.org/10.1016/j.rpor.2013.03.482
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Introduction. Dose escalation in prostate cancer treatment has shown an improvement in local and biochemical control. However,
this carries a risk of increasing toxicity. A reduction in the irradiated volume,with a boost on intraprostatic lesions (IL), determined
by 18F-choline PET/CT facilitate the optimization of the dose to organs at risk (OR).
Objective. To study the feasibility of dose escalation >80Gy in IL, deﬁned by 18F-choline PET/CT, analyzing the dose variation to
organs at risk (OR) in relation to traditional CT planning.
Materials and methods. In 10 patients with prostate cancer, we performed a dynamic PET and a second conventional PET 30min
after injection of 5–7mCi of 18F-choline in a PET/CT-Gemini-TF-Philips. The IL were deﬁned using a ratio of intraprostatic prob-
able lesion “Standardized uptake value” (SUV)/background prostate gland SUV>2. We generated two treatment plans with and
without boost to IL. We compared the dose to 15, 25, 35 and 50% (D15, D25, D35 and D50) of rectal volume in both plans and with
protocol constraints of our service
Results. The rectal dose variation between treatments with and without boost depends on the location of the IL and the relation-
ship between the volume of IL and the whole prostate. Using metabolic information of PET-CT in each patient, the mean increase
in rectal dose was D15:1.4%, D25:1.2%, D35:1% and D50:1.5%. For a distance from IL to the rectum >8mm, the dose increase to
the rectum was negligible. The rectal dose was kept below the constraints of our protocols.
Conclusions. Dose escalation in the IL, deﬁned by 18F-choline PET/CT, represents a slight increase in rectal dose remaining in all
cases within the constrains.
http://dx.doi.org/10.1016/j.rpor.2013.03.483
